Abstract
Purpose of review The present review summarizes and discuss the most recent updated antiemetic consensus. Recent findings Two new neurokinin (NK) 1-receptor antagonists, netupitant and rolapitant, have been approved by the Food and Drug Administration and the European Medicines Agency and incorporated in the latest versions of the MASCC/ESMO, ASCO, and NCCN guidelines. Guidelines all recommend a combination of a serotonin (5-HT) 3-receptor antagonist, dexamethasone, and a NK 1-receptor antagonist in patients receiving highly emetogenic chemotherapy (HEC) with the addition of the multireceptor targeting agent, olanzapine, as an option in cisplatin or anthracycline-cyclophosphamide chemotherapy. A combination of a 5-HT 3-receptor antagonist, dexamethasone, and a NK 1-receptor antagonist is also recommended in patients receiving carboplatin-based chemotherapy, although based on a lower level of evidence. In spite of the development of new antiemetics, nausea has remained a significant adverse effect. Olanzapine is an effective antinausea agent, but sedation can be a problem. Therefore, the effect and tolerability of multitargeting, nonsedative agents like amisulpride, should be explored. Summary Guidelines recommend a combination of a 5-HT 3-receptor antagonist, dexamethasone, and an NK 1-receptor antagonist in HEC and carboplatin-based chemotherapy. The addition of olanzapine can be useful in cisplatin-based and anthracycline-cyclophosphamide-based chemotherapy in particular if the main problem is nausea.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Current Opinion in Oncology |
| Vol/bind | 30 |
| Udgave nummer | 4 |
| Sider (fra-til) | 233–239 |
| ISSN | 1040-8746 |
| DOI | |
| Status | Udgivet - 1 jul. 2018 |